Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Pandox in connection with a directed share issue of approximately SEK 3 billion
Mandate

Vinge has advised Pandox in connection with a directed share issue of approximately SEK 3 billion

November 06, 2019 Capital Markets and Public M&A

Vinge has advised the hotel property owner Pandox in connection with a directed share issue of 16,350,000 class B shares, whereby Pandox will receive approximately SEK 3 billion in issue proceeds.

The subscription price was determined to SEK 186.50 per share through an accelerated book building process. The share issue was directed to approximately 130 Swedish and international institutional investors. The purpose of the share issue is increase the financial flexibility for additional acquisitions and further strengthen the company’s competitive position in the international hotel property market.

Vinge’s team consisted of Jesper Schönbeck, Nils Fredrik Dehlin and Hampus Olsson.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

 Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025